David Endicott has been CEO of Alcon since July 1, 2018.
Mr. Endicott joined Alcon in July 2016 as Chief Operating Officer and President, Commercial & Innovation. He previously served as president of Hospira Infusion Systems. Prior to that, he was an officer and executive committee member of Allergan Inc., where he spent more than 25 years in leadership roles across Europe, Asia, Latin America and the United States.
Mr. Endicott holds a bachelor’s degree in chemistry from Whitman College and a Master of Business Administration from the University of Southern California in the US. He is a graduate of the Harvard Business School Advanced Management Program and previously served on the boards of AdvaMed, Zeltiq Aesthetics Inc. and Orexigen Therapeutics Inc.